# Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer

> **NCT00870337** · PHASE2 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 44 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** everolimus

## Key facts

- **NCT ID:** NCT00870337
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2014-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00870337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00870337, "Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00870337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*